Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HP-6050 in patients with delirium, psychomotor agitation, and irritability
jRCT2031230362Phase 2Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in delirium, psychomotor agitation and irritability comparing HP-6050 microneedle with Placebo microneedle (2 arms). Primary endpoint: Sedation scale at primary assessment timepoint. Started Nov 2023; status: completed.
02
Drugs
HP-6050
03
Conditions
deliriumpsychomotor agitationirritability
Beyond the preview
Go deeper on jRCT2031230362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230362.